CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

GSK to license Hutchmed’s KRAS-EGFR cancer drug for $110M upfront

PartnershipPositive
AI Analysis

Summary

GSK licensed a KRAS-EGFR antibody conjugate from Hutchmed for $110 million upfront plus up to $1.185 billion in milestone payments. The deal represents a significant partnership for Hutchmed's cancer asset.

Importance:7/10
Sentiment:
0.70
licensing dealoncologyKRAS-EGFRantibody conjugateChina
Related Companies

Read the original article

Published by Endpoints News on September 3, 2026 9:59 AM

Read Original